Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4211647 | 0.81 | LPL (0.40) | LPLLIPGIRAK4CA1CA2 | |
| SCHEMBL17268323 | 0.79 | CCR1 (0.45) | LPLLIPGNOS3NOS2IRAK4 | |
| SCHEMBL30286474 | 0.78 | LPL (0.41) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL18342256 | 0.78 | LPL (0.39) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL30086173 | 0.78 | CYP3A4 (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL29562655 | 0.78 | LIPG (0.38) | LPLLIPGIRAK4F11P2RX7 | |
| SCHEMBL201979 | 0.78 | CYP3A4 (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL31631018 | 0.78 | LPL (0.39) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL13576201 | 0.78 | LIPG (0.38) | LPLLIPGIRAK4F11P2RX7 | |
| SCHEMBL1192256 | 0.78 | LPL (0.41) | LPLLIPGIRAK4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815227-B2 | Processes for the preparation of filgotinib | CADILA HEALTHCARE LIMITED (IN) | 2020-10-27 | — | — | US | disclosed |
| US-10815227-B2 | Processes for the preparation of filgotinib | CADILA HEALTHCARE LIMITED (IN) | 2020-10-27 | — | — | US | disclosed |
| US-20200062744-A1 | PROCESSES FOR THE PREPARATION OF FILGOTINIB | CADILA HEALTHCARE LIMITED (IN) | 2020-02-27 | — | — | US | disclosed |
| US-20200062744-A1 | PROCESSES FOR THE PREPARATION OF FILGOTINIB | CADILA HEALTHCARE LIMITED (IN) | 2020-02-27 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8822470-B2 | Substituted pyrido[2,3-b]pyrazines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-10-17 | — | — | US | disclosed |
| US-8450323-B2 | Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| US-20120122835-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8124606-B2 | Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3′,2′-e]pyrazin-6(6aH)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-2389379-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7928105-B2 | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| CN-101687850-A | Substituted pyrimidines as adenosine receptor antagonists | ALMIRALL SA | 2010-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | LPL 2097/4885LIPG 2029/4885NOS3 2420/4885 |
| US-10815227-B2 | Processes for the preparation of filgotinib | ABL1, FER, FLNA | LPL 2391/4885LIPG 338/4885NOS3 1982/4885 |
| US-20120122835-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | LPL 2097/4885LIPG 2029/4885NOS3 2420/4885 |
| US-20200062744-A1 | PROCESSES FOR THE PREPARATION OF FILGOTINIB | ABL1, FER, FLNA | LPL 2391/4885LIPG 338/4885NOS3 1982/4885 |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | PARP1, PARP3, PARP2 | LPL 2097/4885LIPG 2029/4885NOS3 2420/4885 |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | LPL 2097/4885LIPG 2029/4885NOS3 2420/4885 |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | LPL 2097/4885LIPG 2029/4885NOS3 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.